Инсулинорезистентность и ишемический инсульт

   Инсулинорезистентность является самостоятельным фактором риска развития ишемического инсульта (ИИ). Инсулинорезистентность способствует тромбообразованию и развитию атеросклероза, участвуя в основных патогенетических звеньях развития ИИ. Резистентность к инсулину также связана с некоторыми независимыми факторами риска инсульта, такими как гипертензия, гипертриглицеридемия и снижение уровня липопротеинов высокой плотности. Инсулинорезистентность негативно влияет на функциональное восстановление и прогноз у пациентов с ИИ независимо от того, есть ли у пациента сахарный диабет, но механизмы этого недостаточно изучены. Терапия инсулинорезистентности является важным компонентом вторичной профилактики ИИ и включает немедикаментозное и фармакологическое лечение. Представлены терапевтические подходы к инсулинорезистентности, которые позволяют предложить новые терапевтические направления для клинического улучшения прогноза у пациентов с ИИ.

1. Diseases GBD, Injuries C. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–61. doi: 10.1016/S0140-6736(24)00757-8

2. Agrawal R, Reno CM, Sharma S, Christensen C, Huang Y, Fisher SJ. Insulin action in the brain regulates both central and peripheral functions. Am J Physiol Endocrinol Metab. 2021;321(1):E156–e63. doi: 10.1152/ajpendo.00642.2020

3. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453–458. doi: 10.1172/JCI10762

4. Deng XL, Liu Z, Wang C, Li Y, Cai Z. Insulin resistance in ischemic stroke. Metab Brain Dis. 2017;32(5):1323–1334. doi: 10.1007/s11011-017-0050-0

5. Ago T, Matsuo R, Hata J, Wakisaka Y, Kuroda J, Kitazono T, Kamouchi M, Fukuoka Stroke Registry Investigators. Insulin resistance and clinical outcomes after acute ischemic stroke. Neurology. 2018;90(17):e1470–e7. doi: 10.1212/WNL.0000000000005358

6. Rehni AK, Cho S, Dave KR. Ischemic brain injury in diabetes and endoplasmic reticulum stress. Neurochem Int. 2022;152:105219. doi: 10.1016/j.neuint.2021.105219

7. Kullmann S, Kleinridders A, Small DM, Fritsche A, Häring H-U, Preissl H, Heni M. Central nervous pathways of insulin action in the control of metabolism and food intake. Lancet Diabetes Endocrinol. 2020;8(6):524–34. doi: 10.1016/S2213-8587(20)30113-3

8. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: Insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022;7(1):216. doi: 10.1038/s41392-022-01073-0

9. Dienel GA. Brain glucose metabolism: Integration of energetics with function. Physiol Rev. 2018;99(1):949–1045. doi: 10.1152/physrev.00062.2017

10. Magistretti PJ, Allaman I. Lactate in the brain: From metabolic end-product to signalling molecule. Nat Rev Neurosci. 2018;19(4):235–49. doi: 10.1038/nrn.2018.19

11. Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mithieux G, Moreira PI, Murphy MP, Nave K-A, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Swerdlow RH, Millan MJ. Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19(9):609–33. doi: 10.1038/s41573-020-0072-x

12. Huang S, Czech MP. The Glut4 glucose transporter. Cell Metab. 2007;5(4):237–52. doi: 10.1016/j.cmet.2007.03.006

13. Ashrafi G, Wu Z, Farrell RJ, Ryan TA. Glut4 mobilization supports energetic demands of active synapses. Neuron. 2017;93(3):606–15.e3. doi: 10.1016/j.neuron.2016.12.020

14. Scherer T, Sakamoto K, Buettner C. Brain insulin signalling in metabolic homeostasis and disease. Nat Rev Endocrinol. 2021;17(8):468–83. doi: 10.1038/s41574-021-00498-x

15. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in alzheimer’s disease patients is associated with igf-1 resistance, irs-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–38. doi: 10.1172/JCI59903

16. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–223. doi: 10.1152/physrev.00063.2017

17. Liu D, Yang K, Gu H, Li Z, Wang Y, Wang Y. Predictive effect of triglyceride-glucose index on clinical events in patients with acute ischemic stroke and type 2 diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):280. doi: 10.1186/s12933-022-01704-4

18. Shi W, Xing L, Jing L, Tian Y, Yan H, Sun Q, Dai D, Shi L, Liu S. Value of triglyceride-glucose index for the estimation of ischemic stroke risk: insights from a general population. Nutr Metab Cardiovasc Dis. 2020;30:245–53. doi: 10.1016/j.numecd.2019.09.015

19. Guo Y, Zhao J, Zhang Y, Wu L, Yu Z, He D, Huang H, Qu W, Luo X. Triglyceride glucose index influences platelet reactivity in acute ischemic stroke patients. BMC Neurol. 2021;21(1):409. doi: 10.1186/s12883-021-02443-x

20. Chen W, Wang S, Lv W, Pan Y. Causal associations of insulin resistance with coronary artery disease and ischemic stroke: a Mendelian randomization analysis. BMJ Open Diabetes Res Care. 2020;8(1):e001217. doi: 10.1136/bmjdrc-2020-001217

21. Chu LM, Liu CC, Yeh CC, Chang YC, Hu CJ, Shih CC, Cherng YG, Chen TL, Liao CC. Increased diabetes risk and interaction with social and medical events in patients upon stroke: two nationwide studies. Atherosclerosis. 2017;265:87–92. doi: 10.1016/j.atherosclerosis.2017.08.017

22. Hierons SJ, Marsh JS, Wu D, Blindauer CA, Stewart AJ. The interplay between non-esterified fatty acids and plasma zinc and its infl uence on thrombotic risk in obesity and type 2 diabetes. Int J Mol Sci. 2021;22(18). doi: 10.3390/ijms221810140

23. Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, Aboyans V, Bäck M, Badimon L, Cosentino F, De Carlo M, Dorobantu M, Harrison DG, Guzik TJ, Hoefer I, Morris PD, Norata GD, Suades R, Taddei S, Vilahur G, Waltenberger J, Weber C, Wilkinson F, Bochaton-Piallat M-L, Evans PC. Endothelial function in cardiovascular medicine: A consensus paper of the European society of cardiology working groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis. Cardiovasc Res. 2021;117(1):29–42. doi: 10.1093/cvr/cvaa085

24. Muniyappa R, Chen H, Montagnani M, Sherman A, Quon MJ. Endothelial dysfunction due to selective insulin resistance in vascular endothelium: Insights from mechanistic modeling. Am J Physiol Endocrinol Metab. 2020;319(3):E629–e46. doi: 10.1152/ajpendo.00247.2020

25. Potenza AM, Gagliardi S, Nacci C, Carratu RM, Montagnani M. Endothelial dysfunction in diabetes: From mechanisms to therapeutic targets. Curr Medicinal Chem. 2009;16(1):94–112. doi: 10.2174/092986709787002853

26. Den Hartogh DJ, Vlavcheski F, Giacca A, Tsiani E. Attenuation of free fatty acid (Ffa)-induced skeletal muscle cell insulin resistance by resveratrol is linked to activation of ampk and inhibition of mtor and P70 S6k. Int J Mol Sci. 2020;21(14). doi: 10.3390/ijms21144900

27. Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Saccà L, Ferrannini Е. Clustering of insulin resistance with vascular dysfunction and low-grade infl ammation in type 2 diabetes. Diabetes. 2006;55(4):1133–40. doi: 10.2337/diabetes.55.04.06.db051076

28. Hwang DL, Yen CF, Nadler JL. Insulin increases intracellular magnesium transport in human platelets. J Clin Endocrinol Metab. 1993;76(3):549–53. doi: 10.1210/jcem.76.3.8445010

29. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24(8):1476–85. doi: 10.2337/diacare.24.8.1476

30. Feske SK. Ischemic stroke. Am J Med. 2021;134(12):1457–64. doi: 10.1016/j.amjmed.2021.07.027

31. Di Pino A, DeFronzo RA. Insulin resistance and atherosclerosis: Implications for insulin-sensitizing agents. Endocrine Rev. 2019;40(6):1447–67. doi: 10.1210/er.2018-00141

32. Love KM, Liu Z. Dpp4 activity, hyperinsulinemia, and atherosclerosis. J Clin Endocrinol Metab. 2021;106(6):1553–65. doi: 10.1210/clinem/dgab078

33. Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, Karagiannis А. Diabetes and lipid metabolism. Hormones. 2018;17(1):61–7. doi: 10.1007/s42000018-0014-8

34. Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238. doi: 10.1016/j.molmet.2021.101238

35. Zabala A, Darsalia V, Lind M, Svensson AM, Franzén S, Eliasson B, Patrone C, Jonsson M, Nyström T. Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2021;20(1):202. doi: 10.1186/s12933-021-01394-4

36. Li S., Yin C., Zhao W., Zhu H., Xu D., Xu Q., Jiao Y., Wang X., Qiao H. Homeostasis model assessment of insulin resistance in relation to the poor functional outcomes in nondiabetic patients with ischemic stroke. Biosci. Rep. 2018;38(3):BSR20180330. doi: 10.1042/BSR20180330

37. Jing J., Pan Y., Zhao X., Zheng H., Jia Q., Mi D., Chen W., Li H., Liu L., Wang C., He Y., Wang D., Wang Y., Wang Y. Insulin Resistance and Prognosis of Nondiabetic Patients with Ischemic Stroke: The ACROSS-China Study (Abnormal Glucose Regulation in Patients with Acute Stroke Across China). Stroke. 2017;48(4):887–893. doi: 10.1161/STROKEAHA.116.015613

38. Åberg D., Åberg N.D., Jood K., Holmegaard L., Redfors P., Blomstrand C., Isgaard J., Jern C., Svensson J. Homeostasis model assessment of insulin resistance and outcome of ischemic stroke in non-diabetic patients — a prospective observational study. BMC Neurol. 2019;19(1):177. doi: 10.1186/s12883-019-1406-3

39. Diener HC, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: Jacc focus seminar. J Am Coll Cardiol. 2020;75(15):1804–18. doi: 10.1016/j.jacc.2019.12.072

40. Kleindorfer DO, Towfi ghi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith Jr SC, Turan TN, Williams LS. Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American heart Association/American stroke association. Stroke. 2021;52(7):e364–467. doi: 10.1161/str.0000000000000375

41. Baden MY, Shan Z, Wang F, Li Y, Manson JE, Rimm EB, Willett WC, Hu FB, Rexrode KM. Quality of plant-based diet and risk of total, ischemic, and hemorrhagic stroke. Neurology. 2021;96(15):e1940–e53. doi: 10.1212/wnl.0000000000011713

42. Nesti L, Mengozzi A, Tricò D. Impact of nutrient type and sequence on glucose tolerance: Physiological insights and therapeutic implications. Front Endocrinol (Lausanne). 2019;10:144. doi: 10.3389/fendo.2019.00144

43. Jeong SH, Joo HJ, Kwon J, Park E-C. Global, regional, and national burden of stroke and its risk factors, 1990-2019: A systematic analysis for the global burden of disease study 2019. Lancet Neurol. 2021;20(10):795–820. doi: 10.1016/s1474-4422(21)00252-0

44. Saunders DH, Sanderson M, Hayes S, Johnson L, Kramer S, Carter DD, Jarvis H, Brazzelli M, Mead GE. Physical fitness training for stroke patients. Cochrane Database Syst Rev. 2020;3(3):Cd003316. doi: 10.1002/14651858.CD003316.pub7

45. Whillier S. Exercise and insulin resistance. Adv Exp Med Biol. 2020;1228:137–50. doi: 10.1007/978-981-15-1792-1_9

46. Hallschmid M. Intranasal insulin. J Neuroendocrinol (2021) 33(4):e12934. doi: 10.1111/jne.12934

47. Craft S, Raman R, Chow TW, Rafi i MS, Sun CK, Rissman RA, Donohue MC, Brewer JB, Jenkins C, Harless K, Gessert D, Aisen PS. Safety, effi cacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: A randomized clinical trial. JAMA Neurol. 2020;77(9):1099–109. doi: 10.1001/jamaneurol.2020.1840

48. Huang SS, Lu YJ, Huang JP, Wu YT, Day YJ, Hung LM. The essential role of endothelial nitric oxide synthase activation in insulin-mediated neuroprotection against ischemic stroke in diabetes. J Vasc Surg. 2014;59(2):483–91. doi: 10.1016/j.jvs.2013.03.023

49. Lebovitz HE. Thiazolidinediones: The forgotten diabetes medications. Curr Diabetes Rep. 2019;19(12):151. doi: 10.1007/s11892-019-1270-y

50. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams Jr HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med (2016) 374(14):1321–31. doi: 10.1056/NEJMoa1506930

51. Lee M., Saver J.L., Liao H.W., Lin C.H., Ovbiagele B. Pioglitazone for Secondary Stroke Prevention : A Systematic Review and Meta-Analysis. Stroke. 2017;48(2):388–393. doi: 10.1161/STROKEAHA.116.013977

52. Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2019;10(10):Cd010693. doi: 10.1002/14651858.CD010693.pub5

53. Sharma S, Nozohouri S, Vaidya B, Abbruscato T. Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke. Life Sci. 2021;274:119343. doi: 10.1016/j.lfs.2021.119343

54. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–56. doi: 10.1016/j.cmet.2018.03.001

55. Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, Langhans W, Krause E, de Kloet A, Gribble FM, Reimann F, Rinaman L, de Lartigue G, Trapp S. Central and peripheral glp-1 systems independently suppress eating. Nat Metab. 2021;3(2):258–73. doi: 10.1038/s42255-021-00344-4

56. Love KM, Liu J, Regensteiner JG, Reusch JEB, Liu Z. Glp-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. J Diabetes. 2020;12(7):488–98. doi: 10.1111/1753-0407.13045

57. Hanssen R, Kretschmer AC, Rigoux L, Albus K, Edwin Thanarajah S, Sitnikow T, Melzer C, Cornely OA, Brüning JC, Tittgemeyer M. Glp-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. Mol Metab. 2021;45:101163. doi: 10.1016/j.molmet.2021.101163

58. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–13. doi: 10.1016/s2213-8587(17)30412-6

59. Maskery MP, Holscher C, Jones SP, Price CI, Strain WD, Watkins CL, Werring DJ, Emsley HC. Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke : A systematic scoping review. J Cereb Blood Flow Metab. 2021;41(1):14–30. doi: 10.1177/0271678x20952011